Axa
ITOS

Axa’s iTeos Therapeutics ITOS Stock Holding History

Axa’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-218,600
Closed -$2.98M – 1121
2023
Q1 		$2.98M Sell
218,600
-496
-0.2% -$8.89K 0.01% 682
2022
Q4 		$4.28M Sell
219,096
-1,186
-0.5% -$23.2K 0.02% 642
2022
Q3 		$4.2M Buy
220,282
+55,266
+33% +$1.27M 0.02% 611
2022
Q2 		$3.4M Sell
165,016
-53,957
-25% -$1.28M 0.01% 671
2022
Q1 		$7.05M Buy
218,973
+2
+0% +$73 0.02% 557
2021
Q4 		$10.2M Buy
218,971
+2,614
+1% +$87K 0.03% 491
2021
Q3 		$5.84M Buy
216,357
+7,969
+4% +$208K 0.02% 646
2021
Q2 		$5.34M Buy
208,388
+84,686
+68% +$2.02M 0.02% 692
2021
Q1 		$4.23M Buy
+123,702
New +$4.47M 0.01% 733

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa's ITOS Position: Q2 2023 in Review

Axa sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 218,600 shares — an estimated $2.98M sold.

Axa first reported a position in ITOS in Q1 2021 and held it in 9 quarters. The position peaked at $10.2M in Q4 2021. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Axa reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Axa sold 218,600 iTeos Therapeutics shares in Q2 2023, an estimated $2.98M.
  • Axa first reported a position in iTeos Therapeutics in Q1 2021 and held it in 9 quarters.
  • Axa's iTeos Therapeutics position peaked at $10.2M in Q4 2021.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.